Beigene Co. Ltd., of Beijing, said it achieved a $9 million milestone payment relating to its collaboration with Merck Serono, the biopharmaceutical division of Merck KGaA, of Darmstadt, Germany, for BGB-290, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor candidate currently in phase 1 development. Beigene enrolled the fifth patient in the study, which triggered the milestone payment.